Exelixis (EXEL) Financial Analysis & Valuation | Quarter Chart
Exelixis (EXEL)
EXELPrice: $54.28
Fair Value: 🔒
🔒score
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who r... more
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, an... more
Description
Shares
| Market Cap | $13.64B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Michael Morrissey |
| IPO Date | 2000-04-17 | CAGR | 0.28% |
| Employees | 1,147 | Website | www.exelixis.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 7.41% | Total Yield | 7.41% |
EXEL chart loading...
Fundamentals
Technicals
| Enterprise Value | $12.32B | P/E Ratio | 16.25 |
| Forward P/E | 13.57 | PEG Ratio | 0.41 |
| P/S Ratio | 6.22 | P/B Ratio | 7.84 |
| P/CF Ratio | 16.41 | P/FCF Ratio | 16.12 |
| EPS | $3.34 | EPS Growth 1Y | 37.9% |
| EPS Growth 3Y | 533.52% | EPS Growth 5Y | 1373.17% |
| Revenue Growth 1Y | 3.33% | Gross Margin | 0.96% |
| Operating Margin | 0.39% | Profit Margin | 0.35% |
| ROE | 0.4% | ROA | 0.32% |
| ROCE | 0.42% | Current Ratio | 3.26 |
| Quick Ratio | 3.19 | Cash Ratio | 0.61 |
| Debt/Equity | 0.09 | Interest Coverage | — |
| Altman Z Score | 14.87 | Piotroski Score | 7 |